Global Uveitis Treatment Market to Reach $1.1 Billion by 2030
The global market for Uveitis Treatment estimated at US$702.9 Million in the year 2022, is projected to reach a revised size of US$1.1 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2022-2030. Corticosteroids, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$294.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antibiotics segment is readjusted to a revised 5.3% CAGR for the next 8-year period.The U.S. Market is Estimated at $208.1 Million, While China is Forecast to Grow at 5.1% CAGR
The Uveitis Treatment market in the U.S. is estimated at US$208.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$188.5 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.Select Competitors (Total 42 Featured) -
- AbbVie, Inc.
- Alcon, a Novartis Company
- Allergan PLC
- Bausch & Lomb, Inc.
- Enzo Biochem, Inc.
- Hanbell Precise Machinery Co. Ltd.
- Psivida Corporation
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- TopiVert Ltd.
- XOMA Corporation
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Uveitis Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Uveitis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Uveitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for Uveitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for Uveitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Cycloplegic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Cycloplegic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Cycloplegic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 25: USA 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Canada Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: Canada 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- JAPAN
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 29: Japan Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: Japan Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: Japan 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- CHINA
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 32: China Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: China Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: China 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- EUROPE
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 35: Europe Recent Past, Current & Future Analysis for Uveitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 36: Europe Historic Review for Uveitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: Europe 16-Year Perspective for Uveitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 38: Europe Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: Europe Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: Europe 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- FRANCE
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 41: France Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: France Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: France 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- GERMANY
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 44: Germany Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: Germany Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: Germany 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- ITALY
- Table 47: Italy Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 48: Italy Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: Italy 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 50: UK Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: UK Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: UK 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 53: Rest of Europe Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: Rest of Europe Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: Rest of Europe 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Uveitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: Asia-Pacific Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 58: Asia-Pacific 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 59: Rest of World Recent Past, Current & Future Analysis for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 60: Rest of World Historic Review for Uveitis Treatment by Treatment Type - Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 61: Rest of World 16-Year Perspective for Uveitis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressants, Cycloplegic Agents and Other Treatment Types for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Alcon, a Novartis Company
- Allergan PLC
- Bausch & Lomb, Inc.
- Enzo Biochem, Inc.
- Hanbell Precise Machinery Co. Ltd.
- Psivida Corporation
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- TopiVert Ltd.
- XOMA Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 194 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 702.9 Million |
Forecasted Market Value ( USD | $ 1100 Million |
Compound Annual Growth Rate | 5.8% |
Regions Covered | Global |